Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

In Vitro Diagnostics World Market 2016-2026

Posted on: 25 Oct 16

NEW YORK, Oct. 24, 2016 /PRNewswire/ --

Report Details
The In Vitro Diagnostics World Market 2016-2026: Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Genetic Testing, Point of Care Diagnostics, Blood Glucose Testing, Infectious Diseases Testing, Rapid Cardiac Market Testing, Cholesterol Testing, Pregnancy Testing report assesses the global market for IVDs. The market is first split and forecasted by submarket.

Six main submarkets are covered, these are the:
- Point-of-care diagnostics (PoC)
- Clinical chemistry
- Immunochemistry
- Haematology
- Microbiology
- Genetic testing

The leading submarket in the IVD industry at present and throughout the next decade will be point-of-care diagnostics. This submarket is further subdivided into more specific tests. Blood glucose testing accounted for over half of the revenue PoC testing made in 2015 due to the rise in prevalence of diabetes.

What are the prospects in the leading regions and countries?
In our study you will find individual revenue forecasts to 2026 for the leading regional and national markets:
- US
- Japan
- Germany
- France
- UK
- Spain
- Italy
- China
- India
- Brazil
- Russia
- Rest of the World

The US, Japan and China were the 1st 2nd and 3rd leading national markets in 2015 and each will retain its place over the next 10 years. India will be the fastest growing national market from 2015-2026 with China close behind.

Our new report discusses issues and events affecting the IVD market. You will find discussions, including qualitative analyses on:
- The global IVD market
- The IVD market divided by submarket including; point-of-care, clinical chemistry, haematology, immunochemistry, microbiology and genetic testing
- The challenges facing the market, such as the US excise tax on medical devices
- The latest merger & acquisition activity amongst industry leaders
- 11 different national markets including the 'EU5' and 'BRIC' nations

Visiongain predicts that the demand for IVDs will increase in line with the rise in both incidence and prevalence of chronic and infectious diseases. Health professionals will recognise that if these diseases can be diagnosed at the earliest stage possible, then damage to the individual can be minimised in addition to a reduction of later costs to healthcare systems. IVDs will be able to stem the economic and clinical costs of chronic and infectious disease.

The drive to provide patients with diagnostic testing options that are more accurate, easy-to-use and convenient will sustain growth in the IVD market during the forecast period of this report.

Our 166 page report provides 38 tables and 72 figures covering 6 different IVD submarkets. 11 individual national markets are covered in addition to coverage of the leading companies in the industry. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, a primary interview, industry trends, opportunities, and revenue predictions. The increasing prevalence of both chronic and infectious diseases will ensure that there is a great demand for use and innovation of IVDs over the next decade and beyond.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare:
US: (339)-368-6001
Intl: +1 339-368-6001

Editor's Details

Mike Wood

Last updated on: 25/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.